Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
441.16
-13.06 (-2.88%)
NASDAQ · Last Trade: Mar 22nd, 8:44 AM EDT
Detailed Quote
Previous Close
454.22
Open
454.81
Bid
430.00
Ask
457.00
Day's Range
438.87 - 466.90
52 Week Range
265.00 - 615.00
Volume
574,227
Market Cap
7.55B
PE Ratio (TTM)
-34.39
EPS (TTM)
-12.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
387,808
Chart
About Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for liver and metabolic diseases, with an emphasis on addressing non-alcoholic steatohepatitis (NASH) and related conditions. The company’s research and development efforts center around its proprietary drug candidates that target and modulate key metabolic pathways, aiming to improve patient outcomes and provide effective treatment options. By leveraging cutting-edge science and clinical expertise, Madrigal is dedicated to advancing its pipeline of transformative therapies to meet the growing needs of patients suffering from complex liver diseases. Read More
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
